Home
NNVC
NNVC News

Latest NanoViricides Inc. (NNVC) News on July 8, 2024

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

ACCESSWIRE

14 days ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

ACCESSWIRE

18 days ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

ACCESSWIRE

a month ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

ACCESSWIRE

a month ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

ACCESSWIRE

a month ago

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.

ACCESSWIRE

2 months ago

NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

ACCESSWIRE

2 months ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

Associated Press Finance

2 months ago

NanoViricides: Fiscal Q3 Earnings Snapshot

NanoViricides Has Filed its Quarterly Report

ACCESSWIRE

2 months ago

NanoViricides Has Filed its Quarterly Report

A Novel Broad-Spectrum Antiviral with Activity Against RSV

ACCESSWIRE

2 months ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

ACCESSWIRE

2 months ago

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

ACCESSWIRE

2 months ago

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

ACCESSWIRE

2 months ago

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

ACCESSWIRE

2 months ago

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

ACCESSWIRE

5 months ago

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

Associated Press Finance

5 months ago

NanoViricides: Fiscal Q2 Earnings Snapshot

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

ACCESSWIRE

5 months ago

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

ACCESSWIRE

5 months ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

LightPath Technologies Schedules Fiscal 2024 Second Quarter Financial Results Conference Call for February 8, 2024

ACCESSWIRE

5 months ago

LightPath Technologies Schedules Fiscal 2024 Second Quarter Financial Results Conference Call for February 8, 2024

Jayud Announces Entry into Agreements to Acquire Two International Logistics Companies, Embarking on an Acquisition Strategy to Expand Service Offerings and Geographic Footprint

PR Newswire

6 months ago

Jayud Announces Entry into Agreements to Acquire Two International Logistics Companies, Embarking on an Acquisition Strategy to Expand Service Offerings and Geographic Footprint

T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients

GlobeNewswire

6 months ago

T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients

Duos Secures $2.4 Million AI Subscription and Services Agreement

GlobeNewswire

6 months ago

Duos Secures $2.4 Million AI Subscription and Services Agreement

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

GlobeNewswire

6 months ago

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ACCESSWIRE

6 months ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Independent Research Finds 100% Accuracy for Intellicheck Identity Validation Technology

Business Wire

6 months ago

Independent Research Finds 100% Accuracy for Intellicheck Identity Validation Technology

Waldencast plc Announces Receipt of Anticipated Nasdaq Delinquency Notice

GlobeNewswire

6 months ago

Waldencast plc Announces Receipt of Anticipated Nasdaq Delinquency Notice

Cutera, Inc. Announces Preliminary Unaudited Financial Results for Full-Year 2023

Business Wire

6 months ago

Cutera, Inc. Announces Preliminary Unaudited Financial Results for Full-Year 2023

Synlogic Provides Corporate Update and Outlook for 2024

GlobeNewswire

6 months ago

Synlogic Provides Corporate Update and Outlook for 2024

NanoViricides to Present at the Biotech Showcase in San Fransisco

ACCESSWIRE

6 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco

Comstock (LODE) Executes First Commercial Biorefinery Deal

Zacks

6 months ago

Comstock (LODE) Executes First Commercial Biorefinery Deal

Velo3D, Inc. Announces $18 Million Registered Direct Offering

Business Wire

6 months ago

Velo3D, Inc. Announces $18 Million Registered Direct Offering

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

GlobeNewswire

7 months ago

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Lipocine to Present at Biotech Showcase 2024

PR Newswire

7 months ago

Lipocine to Present at Biotech Showcase 2024

Spectaire Launches AireCore™ Into the Oil and Gas Sector

GlobeNewswire

7 months ago

Spectaire Launches AireCore™ Into the Oil and Gas Sector

Velo3D Announces Leadership Transition and Commencement of Strategic Business Review

Business Wire

7 months ago

Velo3D Announces Leadership Transition and Commencement of Strategic Business Review

NextCure Provides Year-End Clinical Pipeline Updates

GlobeNewswire

7 months ago

NextCure Provides Year-End Clinical Pipeline Updates

Loop Media Reports Full Year 2023 and Fourth Quarter Fiscal Financial Results

Business Wire

7 months ago

Loop Media Reports Full Year 2023 and Fourth Quarter Fiscal Financial Results

Life Science Investor Forum Agenda Announced for December 14th, 2023

GlobeNewswire

7 months ago

Life Science Investor Forum Agenda Announced for December 14th, 2023

Spectaire Announces Manufacturing Financing Agreement to Enable Mass Production

GlobeNewswire

7 months ago

Spectaire Announces Manufacturing Financing Agreement to Enable Mass Production

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

GlobeNewswire

7 months ago

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

7 months ago

Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

GlobeNewswire

7 months ago

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

REE Automotive Ltd. (NASDAQ:REE) Q3 2023 Earnings Call Transcript

Insider Monkey

7 months ago

REE Automotive Ltd. (NASDAQ:REE) Q3 2023 Earnings Call Transcript

NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387

News Direct

7 months ago

NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387

PR Newswire

7 months ago

MultiMetaVerse Announces Updates of the Taomee Acqusition and Termination of Prior Acquisition Agreement

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

ACCESSWIRE

7 months ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

BEST Inc. Announces Appointment of Financial Advisor and Legal Counsel to the Special Committee

PR Newswire

8 months ago

BEST Inc. Announces Appointment of Financial Advisor and Legal Counsel to the Special Committee

Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)

Zacks

8 months ago

Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

ACCESSWIRE

8 months ago

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

Associated Press Finance

8 months ago

NanoViricides: Fiscal Q1 Earnings Snapshot

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development

ACCESSWIRE

8 months ago

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development

Investcorp Credit Management BDC, Inc. Announces Financial Results for the Quarter Ended September 30, 2023, and Quarterly and Supplemental Distribution

PR Newswire

8 months ago

Investcorp Credit Management BDC, Inc. Announces Financial Results for the Quarter Ended September 30, 2023, and Quarterly and Supplemental Distribution

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

8 months ago

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

8 months ago

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

8 months ago

Arogo Capital Acquisition Corp. Announces Termination of Merger Agreement with EON Reality, Inc.

All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy

Zacks

8 months ago

All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy

ACRES COMMERCIAL REALTY CORP. ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER DAVID J. BRYANT AND NAMES ELDRON C. BLACKWELL AS SUCCESSOR

PR Newswire

8 months ago

ACRES COMMERCIAL REALTY CORP. ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER DAVID J. BRYANT AND NAMES ELDRON C. BLACKWELL AS SUCCESSOR

Superior Industries International Inc (SUP) Reports Q3 2023 Financial Results

GuruFocus.com

8 months ago

Superior Industries International Inc (SUP) Reports Q3 2023 Financial Results

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

GlobeNewswire

8 months ago

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

Share on Social Networks: